



Joseph M. Pastore et al.

Title: METHOD AND APPARATUS FOR MODULATING CELLULAR METABOLISM DURING

POST-ISCHEMIA OR HEART FAILURE

Docket No.: 279.606US1 Serial No.: 10/645,823

Filed: August 21, 2003 Due Date: N/A

Examiner: Unknown Group Art Unit: 3763

MS Amendment

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

, We are transmitting herewith the following attached items (as indicated with an "X"):

X A return postcard.

X A Supplemental Information Disclosure Statement (2 pgs.), Form 1449 (1 pg.). Documents NOT enclosed.

If not provided for in a separate paper filed herewith, Please consider this a PETITION FOR EXTENSION OF TIME for sufficient number of months to enter these papers and please charge any additional fees or credit overpayment to Deposit Account No. 19-0743.

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.

Customer Number 21186

Atty: T mothy B. Bianchi

Reg. No. 39,610

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this LET May of November, 2004.

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.

(GENERAL)





IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Joseph M. Pastore et al.

Examiner:

Unknown

Serial No.:

10/645,823

Group Art Unit:

3763

Filed:

August 21, 2003

Docket:

279.606US1

Title: N

METHOD AND APPARATUS FOR MODULATING CELLULAR

METABOLISM DURING POST-ISCHEMIA OR HEART FAILURE

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 et. seq., the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicants respectfully request that this Supplemental Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicants request that a copy of the 1449 form, initialed as being considered by the Examiner, be returned to the Applicants with the next official communication.

Pursuant to 37 C.F.R. §1.97(b), it is believed that no fee or statement is required with the Supplemental Information Disclosure Statement. However, if an Office Action on the merits has been mailed, the Commissioner is hereby authorized to charge the required fees to Deposit Account No. 19-0743 in order to have this Supplemental Information Disclosure Statement considered.

Serial No :10 645,823

Filing Date: August 21, 2003

Title: METHOD AND APPARATUS FOR MODULATING CELLULAR METABOLISM DURING POST-ISCHEMIA OR HEART FAILURE

The present application is a U.S. national patent application filed after June 30, 2003. Thus, Applicant believes that the U.S. Patent & Trademark Office has waived the requirement under 37 C.F.R. 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication. The waiver is provided in a pre-OG notice from the U.S. Patent &

Trademark Office entitled "Information Disclosure Statements May Be Filed Without Copies of U.S. Patents and Published Applications in Patent Applications filed after June 30, 2003" and dated July 11, 2003. Applicant acknowledges the requirement to submit copies of foreign patent documents and non-patent literature in accordance with 37 C.F.R. 1.98(a)(2).

The Examiner is invited to contact the Applicants' Representative at the below-listed Telephone number if there are any questions regarding this communication.

Respectfully submitted,

JOSEPH M. PASTORE ET AL.

By their Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A. P.O. Box 2938
Minneapolis, MN 55402

(612) 373-6912

Date Nov. (6, 2004

Timothy E. Bianchi

Reg. No. 39,610

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 1871 day of November, 2004.

Name VI

Signature

PTC CS-CCA (1801)
Approved for use fromigh 10.31 2020 (1901) CS1-CS31
CD Pater & Trademak Office UIO CEPARTMENT OF COMMENT
to Clinical to Lines 1,000 in a U.A. d CLIR control runtbor. Substitute form 1449A/PTO
INFORMATION DISCLOSURE Complete if Known 10/645,823 **Application Number** STATEMENT BY APPLICANT August 21, 2003 Filing Date was as many sheets as necessary) Pastore, Joseph **First Named Inventor** 3763 **Group Art Unit** Unknown **Examiner Name** Attorney Docket No: 279.606US1 Sheet 1 of 1

US PATENT DOCUMENTS				
Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Filing Date If Appropriate
	US- 2002/0099328 A1	07/25/2002	Scheiner, A. , et al.	11/30/2001
	US-4,561,443	12/31/1985	Hogrefe, A. F., et al.	03/08/1983